

=> d his

(FILE 'HOME' ENTERED AT 16:20:09 ON 15 SEP 2006)

FILE 'REGISTRY' ENTERED AT 16:20:23 ON 15 SEP 2006

L1 22 S (BECLOMETHASONE(W)DIPROPIONATE) OR (ALCLOMETHASONE(W)DIPROPIO

FILE 'CAPLUS' ENTERED AT 16:22:24 ON 15 SEP 2006

L2 1779 S L1/THU

FILE 'REGISTRY' ENTERED AT 16:23:00 ON 15 SEP 2006

L3 3 S (MOMETASONE(W)FUROATE) OR (TRIAMCINALONE(W)ACETONIDE)

FILE 'CAPLUS' ENTERED AT 16:23:16 ON 15 SEP 2006

L4 313 S L3/THU

L5 42 S (L2 OR L4) AND (GVHD OR HVGD OR TRANSPLANT OR (GRAFT(W)VERSUS

L6 3 S L5 NOT PY>2000

L7 3 DUP REM L6 (0 DUPLICATES REMOVED)

FILE 'USPATFULL' ENTERED AT 16:25:11 ON 15 SEP 2006

L8 970 S L1 OR L3

L9 73 S (L8) AND (GVHD OR HVGD OR TRANSPLANT OR (GRAFT(W)VERSUS(W)HOS

L10 22 S L9 NOT PY>2001

L11 15727 S CORTICOSTEROI?

L12 7485 S (HGVD OR (HOST-VERSUS-GRAFT) OR (TRANSPLANT(W)REJECTION))

L13 1042 S L11 AND L12 AND TOPICAL

FILE 'MEDLINE' ENTERED AT 16:28:38 ON 15 SEP 2006

L14 50175 S CORTICOSTEROI?

L15 2158 S (HGVD OR (HOST-VERSUS-GRAFT) OR (TRANSPLANT(W)REJECTION))

L16 3 S L14 AND L15 AND TOPICAL

L17 0 S MOMETASONE AND L15

FILE 'REGISTRY' ENTERED AT 16:30:12 ON 15 SEP 2006

L18 1 S MOMETASONE/CN

FILE 'CAPLUS' ENTERED AT 16:30:44 ON 15 SEP 2006

L19 209 S L18

L20 4 S L19 AND L15

L21 0 S L20 NOT PY>2001

L22 16 S CORTICOSTEROID AND LIVER AND (TRANSPLANT(W)REJECTION)

L23 8 S L22 NOT PY>2001

L24 1 S L23 AND TOPICAL

L25 0 S L23 AND (TOPICALLY)

FILE 'MEDLINE, CAPLUS' ENTERED AT 16:34:34 ON 15 SEP 2006

L26 3 S CORTICOSTEROID AND (HVGD OR HOST(W)VERSUS(W)GRAFT)

L27 374 S (HEART(W)TRANSPAN?) AND CORTICOSTEROI?

=>

FILE 'HOME' ENTERED AT 16:20:09 ON 15 SEP 2006

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:20:23 ON 15 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1
DICTIONARY FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer
be available. Please contact CAS Customer Care
(<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s (beclo methasone(w) dipropionate) or (alclomethasone(w) dipropionate) or
busedonide or (beclo methasone-17-monopropionate) or (clobetasol(w) propionate) or
(diflorasone(w) diacetate) or flunisolide or flurandrenolide or
(fluticasone(w) propionate) or (halobetasol(w) propionate) or halcinocide

12 BECLOMETHASONE
985 DIPROPIONATE
4 BECLOMETHASONE (W) DIPROPIONATE
1 ALCLOMETHASONE
985 DIPROPIONATE
0 ALCLOMETHASONE (W) DIPROPIONATE
0 BUSEDONIDE
12 BECLOMETHASONE
576904 17
89 MONOPROPIONATE
1 BECLOMETHASONE-17-MONOPROPIONATE
(BECLOMETHASONE (W) 17 (W) MONOPROPIONATE)
5 CLOBETASOL
13215 PROPIONATE
2 CLOBETASOL (W) PROPIONATE
9 DIFLORASONE
74270 DIACETATE
1 DIFLORASONE (W) DIACETATE
9 FLUNISOLIDE
1 FLURANDRENOLIDE
7 FLUTICASONE
13215 PROPIONATE
3 FLUTICASONE (W) PROPIONATE
2 HALOBETASOL

13215 PROPIONATE
 1 HALOBETASOL(W) PROPIONATE
 0 HALCINOCIDE
 L1 22 (BECLOMETHASONE(W)DIPROPIONATE) OR (ALCLOMETHASONE(W)DIPROPIONAT
 E) OR BUSEDONIDE OR (BECLOMETHASONE-17-MONOPROPIONATE) OR (CLOBE
 TASOL(W) PROPIONATE) OR (DIFLORASONE(W)DIACETATE) OR FLUNISOLIDE
 OR FLURANDRENOLIDE OR (FLUTICASONE(W) PROPIONATE) OR (HALOBETASOL(
 W) PROPIONATE) OR HALCINOCIDE

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	91.76	91.97

FILE 'CAPLUS' ENTERED AT 16:22:24 ON 15 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2006 VOL 145 ISS 13
 FILE LAST UPDATED: 14 Sep 2006 (20060914/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1/thu

2674 L1
 811475 THU/RL
 L2 1779 L1/THU
 (L1 (L) THU/RL)

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.41	94.38

FILE 'REGISTRY' ENTERED AT 16:23:00 ON 15 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1
 DICTIONARY FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care

(<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s (mometasone(w)furoate) or (triamcinalone(w)acetone)
      5 MOMETASONE
    1085 FUROATE
      3 MOMETASONE(W)FUROATE
      0 TRIAMCINALONE
    454 ACETONIDE
      0 TRIAMCINALONE(W)ACETONIDE
L3      3 (MOMETASONE(W)FUROATE) OR (TRIAMCINALONE(W)ACETONIDE)
```

```
=> file caplus
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                19.48      113.86
```

FILE 'CAPLUS' ENTERED AT 16:23:16 ON 15 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 14 Sep 2006 (20060914/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s 13/thu
      388 L3
    811475 THU/RL
L4      313 L3/THU
          (L3 (L) THU/RL)
```

```
=> s (L2 or L4) and (GVHD or HVGD or transplant or (graft(w)versus(w)host) or
(host(w)versus(w)graft))
      2549 GVHD
      12 HVGD
    56884 TRANSPLANT
    99924 GRAFT
```

```

31610 VERSUS
204334 HOST
1721 GRAFT(W)VERSUS(W)HOST
204334 HOST
31610 VERSUS
99924 GRAFT
33 HOST(W)VERSUS(W)GRAFT
L5      42 (L2 OR L4) AND (GVHD OR HVGD OR TRANSPLANT OR (GRAFT(W)VERSUS(W)
        HOST) OR (HOST(W)VERSUS(W)GRAFT))

```

```

=> s l5 not py>2000
      6254016 PY>2000
L6      3 L5 NOT PY>2000

```

```

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7      3 DUP REM L6 (0 DUPLICATES REMOVED)

```

```

=> d l7 1-3 ti

```

```

L7      ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI      Bronchoalveolar lavage cellular profiles in lung transplantation: the
        effect of inhaled corticosteroids

```

```

L7      ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI      Oral beclomethasone dipropionate for treatment of intestinal graft
        -versus-host disease: a randomized, controlled trial

```

```

L7      ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI      Oral beclomethasone dipropionate for treatment of human intestinal
        graft-versus-host disease

```

```

=> file uspatfull
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE ENTRY 23.82
TOTAL SESSION 137.68

```

```

FILE 'USPATFULL' ENTERED AT 16:25:11 ON 15 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

```

```

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 14 Sep 2006 (20060914/PD)
FILE LAST UPDATED: 14 Sep 2006 (20060914/ED)
HIGHEST GRANTED PATENT NUMBER: US7107620
HIGHEST APPLICATION PUBLICATION NUMBER: US2006206975
CA INDEXING IS CURRENT THROUGH 12 Sep 2006 (20060912/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 14 Sep 2006 (20060914/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006

```

```

=> s (L2 or L4) and (GVHD or HVGD or transplant or (graft(w)versus(w)host) or
(host(w)versus(w)graft))
'THU' IS NOT A VALID CROSSOVER QUALIFIER FOR
Answer sets created in a different file may be field qualified with a
limited set of qualifiers. Enter HELP CROSSOVER at an arrow prompt
(=>) for specific information.

```

```

=> s l1 or l3
      919 L1
      186 L3
L8      970 L1 OR L3

```

```

=> s (L8) and (GVHD or HVGD or transplant or (graft(w)versus(w)host) or
(host(w)versus(w)graft))

```

2422 GVHD
 28 HVGD
 25351 TRANSPLANT
 69620 GRAFT
 238680 VERSUS
 286870 HOST
 7721 GRAFT (W) VERSUS (W) HOST
 286870 HOST
 238680 VERSUS
 69620 GRAFT
 911 HOST (W) VERSUS (W) GRAFT
 L9 73 (L8) AND (GVHD OR HVGD OR TRANSPLANT OR (GRAFT (W) VERSUS (W) HOST)
 OR (HOST (W) VERSUS (W) GRAFT))

=> s l9 not py>2001
 1637458 PY>2001
 L10 22 L9 NOT PY>2001

=> d l10 1-22 ti

L10 ANSWER 1 OF 22 USPATFULL on STN
 TI Solid matrix therapeutic compositions

L10 ANSWER 2 OF 22 USPATFULL on STN
 TI Method and means for treating glomerulonephritis

L10 ANSWER 3 OF 22 USPATFULL on STN
 TI Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

L10 ANSWER 4 OF 22 USPATFULL on STN
 TI Methods and compositions for modulating responsiveness to corticosteroids

L10 ANSWER 5 OF 22 USPATFULL on STN
 TI Pharmaceutical compositions having steroid nitrate ester derivatives useful as anti-inflammatory drugs

L10 ANSWER 6 OF 22 USPATFULL on STN
 TI Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same

L10 ANSWER 7 OF 22 USPATFULL on STN
 TI Delivery of drugs to the lower gastrointestinal tract

L10 ANSWER 8 OF 22 USPATFULL on STN
 TI Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs

L10 ANSWER 9 OF 22 USPATFULL on STN
 TI Steroid nitrite ester derivatives useful as anti-inflammatory drugs

L10 ANSWER 10 OF 22 USPATFULL on STN
 TI Steroid nitrite/nitrate ester derivatives useful as anti-inflammatory drugs

L10 ANSWER 11 OF 22 USPATFULL on STN
 TI Sunscreen-wound healing compositions and methods for preparing and using same

L10 ANSWER 12 OF 22 USPATFULL on STN
 TI Antifungal wound healing compositions and methods for preparing and using same

L10 ANSWER 13 OF 22 USPATFULL on STN
 TI Bioadhesive-wound healing compositions and methods for preparing and using same

L10 ANSWER 14 OF 22 USPATFULL on STN
 TI Method for topical inhibition of the metabolic activity of cytochrome P450

L10 ANSWER 15 OF 22 USPATFULL on STN
 TI Anti-inflammatory wound healing compositions and methods for preparing and using same

L10 ANSWER 16 OF 22 USPATFULL on STN
 TI Targeted drug delivery via phosphonate derivatives

L10 ANSWER 17 OF 22 USPATFULL on STN
 TI Dermatological wound healing compositions and methods for preparing and using same

L10 ANSWER 18 OF 22 USPATFULL on STN
 TI Use of liquid fluorocarbons to facilitate pulmonary drug delivery

L10 ANSWER 19 OF 22 USPATFULL on STN
 TI Targeted drug delivery via phosphonate derivatives

L10 ANSWER 20 OF 22 USPATFULL on STN
 TI Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them

L10 ANSWER 21 OF 22 USPATFULL on STN
 TI Method of treatment of inflamed tissues

L10 ANSWER 22 OF 22 USPATFULL on STN
 TI Targeted drug delivery via phosphonate derivatives

=> d l10 3 4 7 21 ti abs bib

L10 ANSWER 3 OF 22 USPATFULL on STN
 TI Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

AB A method for preventing tissue damage associated with graft-versus-host disease in a patient having undergone hematopoietic cell transplantation, and host-versus-graft disease in a patient having undergone organ allograft transplantation. The method includes orally administering to the patient a prophylactically effective amount of a topically active corticosteroid, such as beclomethasone dipropionate, for a period of time following hematopoietic cell or organ allograft transplantation, and prior to the presentation of symptoms associated with graft-versus-host disease or host-versus-graft disease. Representative tissues includes tissue of the intestine and liver, while representative tissue damage includes inflammation thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:98416 USPATFULL
 TI Method for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

IN McDonald, George B., Bellevue, WA, United States
 PA Institute for Drug Research, Inc., New York, NY, United States (U.S.)

corporation)
PI US 6096731 20000801
AI US 1998-151388 19980910 (9)
RLI Continuation-in-part of Ser. No. US 1998-103762, filed on 24 Jun 1998
DT Utility
FS Granted
EXNAM Primary Examiner: Krass, Frederick
LREP Ohlandt, Greeley, Ruggiero & Perle
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 22 USPATFULL on STN

TI Methods and compositions for modulating responsiveness to corticosteroids
AB Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN- γ in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon- γ inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN- γ in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2000:50737 USPATFULL
TI Methods and compositions for modulating responsiveness to corticosteroids
IN Sekut, Les, Westborough, MA, United States
Carter, Adam, Newburyport, MA, United States
Ghayur, Tariq, Grafton, MA, United States
Banerjee, Subhashis, Shrewsbury, MA, United States
Tracey, Daniel E., Harvard, MA, United States
PA BASF Aktiengesellschaft, Rheinland Pfalz, Germany, Federal Republic of (non-U.S. corporation)
PI US 6054487 20000425
AI US 1997-820692 19970318 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Jarvis, William R. A.
LREP Lahive & Cockfield, LLP
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 2404
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 22 USPATFULL on STN

TI Delivery of drugs to the lower gastrointestinal tract
AB Diseases of the colon are treated by oral ingestion of a unit dosage form containing a plurality of porous microscopic beads, the pores

containing an active agent or drug and plugged with a polysaccharide that is chemically degradable by colon-specific bacteria. The dosage form further contains a coating of an enteric material that remains intact until the dosage form reaches the colon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 1998:156948 USPATFULL
TI Delivery of drugs to the lower gastrointestinal tract
IN Berliner, David L., Atherton, CA, United States
Nacht, Sergio, Redwood City, CA, United States
PA Advanced Polymer Systems, Inc., Redwood City, CA, United States (U.S. corporation)
PI US 5849327 19981215
AI US 1996-720335 19960927 (8)
RLI Continuation-in-part of Ser. No. US 1995-432619, filed on 2 May 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-282836, filed on 29 Jul 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Heller Ehrman White & McAuliffe
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 685

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 22 USPATFULL on STN

TI Method of treatment of inflamed tissues
AB A method of and composition for concentrating a therapeutic agent in an inflamed dermal region are disclosed. The composition, which is also used in the method, is a liposomal composition. The liposomes contain the therapeutic agent in entrapped form and are composed of vesicle-forming lipids including a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer. After intravenous administration, the liposomes are taken up by the inflamed region within 24-48 hours, for site-specific release of entrapped compound into the inflamed region.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 94:90795 USPATFULL
TI Method of treatment of inflamed tissues
IN Woodle, Martin C., Menlo Park, CA, United States
Martin, Francis J., San Francisco, CA, United States
Huang, Shi K., Castro Valley, CA, United States
PA Liposome Technology, Inc., Menlo Park, CA, United States (U.S. corporation)
PI US 5356633 19941018
AI US 1992-958100 19921007 (7)
RLI Continuation-in-part of Ser. No. US 1991-642321, filed on 15 Jan 1991, now patented, Pat. No. US 5213804 which is a continuation-in-part of Ser. No. US 1989-425224, filed on 20 Oct 1989, now patented, Pat. No. US 5013556
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Spear, James M.
LREP Stratford, Carol A., Dehlinger, Peter J.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 27 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 2209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> s corticosteroi?
L11      15727 CORTICOSTEROI?

=> s (HGVD or (host-versus-graft) or (transplant(w)rejection))
      1 HGVD
      286870 HOST
      238680 VERSUS
      69620 GRAFT
      911 HOST-VERSUS-GRAFT
          (HOST (W) VERSUS (W) GRAFT)
      25351 TRANSPLANT
      73831 REJECTION
      6891 TRANSPLANT(W) REJECTION
L12      7485 (HGVD OR (HOST-VERSUS-GRAFT) OR (TRANSPLANT(W) REJECTION))

=> s l11 and l12 and topical
      85868 TOPICAL
L13      1042 L11 AND L12 AND TOPICAL
```

```
=> file medline
COST IN U.S. DOLLARS                               SINCE FILE      TOTAL
                                                ENTRY      SESSION
FULL ESTIMATED COST                             17.08      154.76
```

FILE 'MEDLINE' ENTERED AT 16:28:38 ON 15 SEP 2006

FILE LAST UPDATED: 14 Sep 2006 (20060914/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s corticosteroi?
L14      50175 CORTICOSTEROI?

=> s (HGVD or (host-versus-graft) or (transplant(w)rejection))
      0 HGVD
      163038 HOST
      219031 VERSUS
      146858 GRAFT
      286 HOST-VERSUS-GRAFT
          (HOST (W) VERSUS (W) GRAFT)
      66306 TRANSPLANT
      59875 REJECTION
      1873 TRANSPLANT(W) REJECTION
L15      2158 (HGVD OR (HOST-VERSUS-GRAFT) OR (TRANSPLANT(W) REJECTION))

=> s l14 and l15 and topical
      56678 TOPICAL
```

L16 3 L14 AND L15 AND TOPICAL

=> d l16 1-3 ti

L16 ANSWER 1 OF 3 MEDLINE on STN

TI Immunomodulatory therapy in ophthalmology - is there a place for topical application?.

L16 ANSWER 2 OF 3 MEDLINE on STN

TI Therapeutic potential of macrolide immunosuppressants in dermatology.

L16 ANSWER 3 OF 3 MEDLINE on STN

TI Subepithelial infiltrates: a probable sign of corneal transplant rejection.

=> s mometasone and l15

318 MOMETASONE

L17 0 MOMETASONE AND L15

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.17

155.93

FILE 'REGISTRY' ENTERED AT 16:30:12 ON 15 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

DICTIONARY FILE UPDATES: 14 SEP 2006 HIGHEST RN 906714-10-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Effective September 24, 2006, Concord 3D coordinates will no longer be available. Please contact CAS Customer Care (<http://www.cas.org/supp.html>) if you have a need for 3D coordinates.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s mometasone/cn

L18 1 MOMETASONE/CN

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

5.20

161.13

FILE 'CAPLUS' ENTERED AT 16:30:44 ON 15 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2006 VOL 145 ISS 13
FILE LAST UPDATED: 14 Sep 2006 (20060914/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l18

L19 209 L18

=> s l19 and l15

0 HGVD
204334 HOST
31610 VERSUS
99924 GRAFT
33 HOST-VERSUS-GRAFT
(HOST(W) VERSUS(W) GRAFT)
56884 TRANSPLANT
34530 REJECTION
10849 TRANSPLANT(W) REJECTION

L20 4 L19 AND L15

=> d l20 1-4 ti

L20 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases

L20 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions containing a cyclooxygenase-2 inhibitor and a corticosteroid

L20 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions for treating T cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency

L20 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions using thalidomide or other angiogenesis-inhibitory compound and anti-inflammatory agent for inhibition of angiogenesis

=> s l20 not py>2001

5314894 PY>2001

L21 0 L20 NOT PY>2001

=> s corticosteroid and liver and (transplant(w) rejection)
21981 CORTICOSTEROID

546514 LIVER
56884 TRANSPLANT
34530 REJECTION
10849 TRANSPLANT(W) REJECTION
L22 16 CORTICOSTEROID AND LIVER AND (TRANSPLANT(W) REJECTION)

=> s l22 not py>2001
5314894 PY>2001
L23 8 L22 NOT PY>2001

=> d l23 1-8 ti

L23 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Adult liver transplantation and steroid-azathioprine withdrawal
in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a
prospective study

L23 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Daclizumab A review of its use in the management of organ transplantation

L23 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Steroid elimination 24 hours after liver transplantation using
daclizumab, tacrolimus, and mycophenolate mofetil

L23 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Safety and efficacy of TOR inhibitors and other immunosuppressive regimens
in African-American renal transplant recipients

L23 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Long-term outcome of systemic cyclosporine treatment following penetrating
keratoplasty

L23 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Tacrolimus-based dual therapy is as efficacious and safe as the
conventional tacrolimus-based triple therapy in liver
transplantation

L23 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Long term management of liver transplant
rejection in children

L23 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
TI Effects of corticosteroids on HCV infection

=> s l23 and topical
42422 TOPICAL
L24 1 L23 AND TOPICAL

=> d l24 1 ti abs bib

L24 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Long-term outcome of systemic cyclosporine treatment following penetrating
keratoplasty
AB The authors performed a retrospective study to evaluate the long-term
outcome of systemic cyclosporine treatment as an adjunct to
topical corticosteroid treatment after penetrating
keratoplasty (PKP). Twenty-six high-risk patients (27 eyes) who received
systemic cyclosporine following PKP for an average of 5.4 mo were compared
with another series of 57 patients (57 eyes) who did not receive
cyclosporine after PKP. Endothelial rejection developed in 2 cases during
cyclosporine treatment and in 6 cases after discontinuation. The rate of
rejection-free graft survival was similar between the treated and the
control groups. The control group showed a significantly higher rate of

graft survival than the treated group. As side effects in the treatment group, transient elevation in blood urea nitrogen or creatine developed in 7 cases. Increase in glutamate oxaloacetate transaminase (GOT) or glutamate pyruvate transaminase (GPT) developed in 4 cases. Severe side effects were absent throughout the series in both groups of patients. Systemic cyclosporine treatment for several months did not reduce the incidence of rejection nor improve the rate of graft clarity in the long term in high-risk patients after PKP.

AN 2001:563278 CAPLUS
 DN 136:303739
 TI Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty
 AU Inoue, K.; Kimura, C.; Amano, S.; Sato, T.; Fujita, N.; Kagaya, F.; Kaji, Y.; Tsuru, T.; Araie, M.
 CS Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan
 SO Japanese Journal of Ophthalmology (2001), 45(4), 378-382
 CODEN: JJOPA7; ISSN: 0021-5155
 PB Elsevier Science Inc.
 DT Journal
 LA English
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l23 and (topically)
 10159 TOPICALLY
 L25 0 L23 AND (TOPICALLY)

=> file medline caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.76	197.89
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-0.75

FILE 'MEDLINE' ENTERED AT 16:34:34 ON 15 SEP 2006

FILE 'CAPLUS' ENTERED AT 16:34:34 ON 15 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s corticosteroid and (HVGD or host(w)versus(w)graft)
 L26 3 CORTICOSTEROID AND (HVGD OR HOST(W) VERSUS(W) GRAFT)

=> d l26 1-3 ti

L26 ANSWER 1 OF 3 MEDLINE on STN
 TI Engraftment syndrome following hematopoietic stem cell transplantation.

L26 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Method of treatment of cancer by controlling graft-versus-leukemia using topical active corticosteroids

L26 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 TI Method using oral administration of a topically active corticosteroid for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

=> d 126 3 ti abs bib

L26 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI Method using oral administration of a topically active corticosteroid for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

AB A method is provided for preventing tissue damage associated with graft-vs.-host disease in a patient having undergone hematopoietic cell transplantation, and host-vs.-graft disease in a patient having undergone organ allograft transplantation. The method includes orally administering to the patient a prophylactically effective amount of a topically active corticosteroid, such as beclomethasone dipropionate, for a period of time following hematopoietic cell or organ allograft transplantation, and prior to the presentation of symptoms associated with graft-vs.-host disease or host-vs.-graft disease. Representative tissues includes tissue of the intestine and liver, while representative tissue damage includes inflammation thereof.

AN 2000:531659 CAPLUS

DN 133:115533

TI Method using oral administration of a topically active corticosteroid for preventing tissue damage associated with graft-versus-host or host-versus-graft disease following transplantation

IN McDonald, George B.

PA Institute for Drug Research, Inc., USA

SO U.S., 5 pp., Cont.-in-part of U.S. Ser. No. 103,762.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6096731	A	20000801	US 1998-151388	19980910
	CA 2413883	AA	20011129	CA 2000-2413883	20000522
	WO 2001089529	A1	20011129	WO 2000-US14064	20000522
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1998-103762	A2	19980624		
	US 1998-151388	A	19980910		
	WO 2000-US14064	W	20000522		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (heart(w)transplan?) and corticosteroi?

L27 374 (HEART(W) TRANSPLAN?) AND CORTICOSTEROI?

=> d his

(FILE 'HOME' ENTERED AT 16:20:09 ON 15 SEP 2006)

FILE 'REGISTRY' ENTERED AT 16:20:23 ON 15 SEP 2006

L1 22 S (BECLOMETHASONE(W)DIPROPIONATE) OR (ALCLOMETHASONE(W)DIPROPIO

FILE 'CAPLUS' ENTERED AT 16:22:24 ON 15 SEP 2006

L2 1779 S L1/THU

FILE 'REGISTRY' ENTERED AT 16:23:00 ON 15 SEP 2006
 L3 3 S (MOMETASONE(W)FUROATE) OR (TRIAMCINALONE(W)ACETONIDE)

FILE 'CAPLUS' ENTERED AT 16:23:16 ON 15 SEP 2006
 L4 313 S L3/THU
 L5 42 S (L2 OR L4) AND (GVHD OR HVGD OR TRANSPLANT OR (GRAFT(W)VERSUS
 L6 3 S L5 NOT PY>2000
 L7 3 DUP REM L6 (0 DUPLICATES REMOVED)

FILE 'USPATFULL' ENTERED AT 16:25:11 ON 15 SEP 2006
 L8 970 S L1 OR L3
 L9 73 S (L8) AND (GVHD OR HVGD OR TRANSPLANT OR (GRAFT(W)VERSUS(W)HOS
 L10 22 S L9 NOT PY>2001
 L11 15727 S CORTICOSTEROI?
 L12 7485 S (HGVD OR (HOST-VERSUS-GRAFT) OR (TRANSPLANT(W)REJECTION))
 L13 1042 S L11 AND L12 AND TOPICAL

FILE 'MEDLINE' ENTERED AT 16:28:38 ON 15 SEP 2006
 L14 50175 S CORTICOSTEROI?
 L15 2158 S (HGVD OR (HOST-VERSUS-GRAFT) OR (TRANSPLANT(W)REJECTION))
 L16 3 S L14 AND L15 AND TOPICAL
 L17 0 S MOMETASONE AND L15

FILE 'REGISTRY' ENTERED AT 16:30:12 ON 15 SEP 2006
 L18 1 S MOMETASONE/CN

FILE 'CAPLUS' ENTERED AT 16:30:44 ON 15 SEP 2006
 L19 209 S L18
 L20 4 S L19 AND L15
 L21 0 S L20 NOT PY>2001
 L22 16 S CORTICOSTEROID AND LIVER AND (TRANSPLANT(W)REJECTION)
 L23 8 S L22 NOT PY>2001
 L24 1 S L23 AND TOPICAL
 L25 0 S L23 AND (TOPICALLY)

FILE 'MEDLINE, CAPLUS' ENTERED AT 16:34:34 ON 15 SEP 2006
 L26 3 S CORTICOSTEROID AND (HVGD OR HOST(W)VERSUS(W)GRAFT)
 L27 374 S (HEART(W)TRANSPLAN?) AND CORTICOSTEROI?